Literature DB >> 25035145

Targeted diphtheria toxin to treat BPDCN.

David J FitzGerald1.   

Abstract

In this issue of Blood, Frankel et al describe a novel treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) using an engineered version of diphtheria toxin that is targeted to malignant cells via a fusion with interleukin (IL)3 (see panel A).

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25035145      PMCID： PMC4102704          DOI： 10.1182/blood-2014-06-578633

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  9 in total

1.  Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

Authors:  Arthur E Frankel; Jung H Woo; Chul Ahn; Naveen Pemmaraju; Bruno C Medeiros; Hetty E Carraway; Olga Frankfurt; Stephen J Forman; Xuezhong A Yang; Marina Konopleva; Francine Garnache-Ottou; Fanny Angelot-Delettre; Christopher Brooks; Michael Szarek; Eric Rowinsky
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

2.  Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors ("hematogones") and B lymphoblastic leukemia blasts.

Authors:  Nagwa M Hassanein; Felisa Alcancia; Kathryn R Perkinson; Patrick J Buckley; Anand S Lagoo
Journal:  Am J Clin Pathol       Date:  2009-10       Impact factor: 2.493

3.  Toxicity of diphtheria toxin for lymphoblastoid cells is increased by conjugation to antilymphocytic globulin.

Authors:  P E Thorpe; W C Ross; A J Cumber; C A Hinson; D C Edwards; A J Davies
Journal:  Nature       Date:  1978-02-23       Impact factor: 49.962

4.  Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

Authors:  Robert J Kreitman; Martin S Tallman; Tadeusz Robak; Steven Coutre; Wyndham H Wilson; Maryalice Stetler-Stevenson; David J Fitzgerald; Robert Lechleider; Ira Pastan
Journal:  J Clin Oncol       Date:  2012-02-21       Impact factor: 44.544

Review 5.  Immunotoxins for leukemia.

Authors:  Alan S Wayne; David J Fitzgerald; Robert J Kreitman; Ira Pastan
Journal:  Blood       Date:  2014-02-27       Impact factor: 22.113

Review 6.  Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity?

Authors:  Francine Garnache-Ottou; Jean Feuillard; Philippe Saas
Journal:  Br J Haematol       Date:  2007-02       Impact factor: 6.998

7.  Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.

Authors:  Ronit Mazor; Jaime A Eberle; Xiaobo Hu; Aaron N Vassall; Masanori Onda; Richard Beers; Elizabeth C Lee; Robert J Kreitman; Byungkook Lee; David Baker; Chris King; Raffit Hassan; Itai Benhar; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-05       Impact factor: 12.779

8.  Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.

Authors:  Masanori Onda; Kamran Ghoreschi; Scott Steward-Tharp; Craig Thomas; John J O'Shea; Ira H Pastan; David J FitzGerald
Journal:  J Immunol       Date:  2014-06-02       Impact factor: 5.426

9.  CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies.

Authors:  Ugo Testa; Elvira Pelosi; Arthur Frankel
Journal:  Biomark Res       Date:  2014-02-10
  9 in total
  6 in total

1.  DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.

Authors:  Katsuhiro Togami; Timothy Pastika; Jason Stephansky; Mahmoud Ghandi; Amanda L Christie; Kristen L Jones; Carl A Johnson; Ross W Lindsay; Christopher L Brooks; Anthony Letai; Jeffrey W Craig; Olga Pozdnyakova; David M Weinstock; Joan Montero; Jon C Aster; Cory M Johannessen; Andrew A Lane
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

Review 2.  CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Authors:  Elodie Bôle-Richard; Naveen Pemmaraju; Blandine Caël; Etienne Daguindau; Andrew A Lane
Journal:  Cancers (Basel)       Date:  2022-05-03       Impact factor: 6.575

Review 3.  A new palliative treatment for blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature.

Authors:  Yunning Yang; Yuanyuan Xu; You Nie; Hongwei Wang; Shan Long; Xiaosong Li
Journal:  J Int Med Res       Date:  2019-09-17       Impact factor: 1.671

Review 4.  Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  Kah Keng Wong; Rosline Hassan; Nik Soriani Yaacob
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

5.  Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.

Authors:  Naveen Pemmaraju; Marina Konopleva
Journal:  Blood Adv       Date:  2020-08-25

6.  Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern.

Authors:  Nathalie Fournier; Emilie Jacque; Alexandre Fontayne; Delphine Derache; Gilles Dupont; Lucie Verhaeghe; Linda Baptista; Aurélie Dehenne; Anne-Sophie Dezetter; Aurélie Terrier; Alain Longue; Virginie Pochet-Beghin; Cecile Beghin; Sami Chtourou; Christophe de Romeuf
Journal:  MAbs       Date:  2018-04-10       Impact factor: 5.857
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.